Inhibition of endothelin ETB receptor system aggravates neointimal hyperplasia after balloon injury of rat carotid artery

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 3, 2009, Pages 998-1004

  Kitada, Kento ^a   Yui, Nozomi ^a   Matsumoto, Chika ^a   Mori, Tatsuhiko ^a   Ohkita, Mamoru ^a   Matsumura, Yasuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 7 [2 (2 CARBOXYPROPYL) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; 4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; ATRASENTAN; ENDOTHELIN B RECEPTOR; HYDRALAZINE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BODY WEIGHT; CAROTID ARTERY INJURY; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD; CAROTID ARTERY; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; HYPERPLASIA; INTIMA; METABOLISM; PATHOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; SPRAGUE DAWLEY RAT; TRANSGENIC RAT;

ANGIOPLASTY, BALLOON; ANIMALS; CAROTID ARTERIES; CAROTID ARTERY INJURIES; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HYPERPLASIA; MALE; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; TUNICA INTIMA;

EID: 73349087197     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.157065     Document Type: Article

References (40)

1. Clozel M, Gray GA, Breu V, Löffler BM, and Osterwalder R (1992) The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 186:867-873.
2. Douglas JS Jr (2007) Pharmacologic approaches to restenosis prevention. Am J Cardiol 100:10K-16K.
3. Douglas SA, Louden C, Vickery-Clark LM, Storer BL, Hart T, Feuerstein GZ, Elliott JD, and Ohlstein EH (1994) A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res 75:190-197.
4. Elmarakby AA, Dabbs Loomis E, Pollock JS, and Pollock DM (2004) ETA receptor blockade attenuates hypertension and decreases reactive oxygen species in ETB receptor-deficient rats. J Cardiovasc Pharmacol 44:S7-S10.
5. Erglis A, Narbute I, Kumsars I, Jegere S, Mintale I, Zakke I, Strazdins U, and Saltups A (2007) A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 50:491-497.
6. Farb A and Boam AB (2007) Stent thrombosis redux-the FDA perspective. N Engl J Med 356:984-987.
7. Ferrer P, Valentine M, Jenkins-West T, Weber H, Goller NL, Durham SK, Molloy CJ, and Moreland S (1995) Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries. J Cardiovasc Pharmacol 26:908-915.
8. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, and Nishikibe M (1994) Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 199:1461-1465.
9. Garg UC and Hassid A (1989) Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774-1777.
10. Gariepy CE, Williams SC, Richardson JA, Hammer RE, and Yanagisawa M (1998) Transgenic expression of the endothelin-B receptor prevents congenital intestinal aganglionosis in a rat model of Hirschsprung disease. J Clin Invest 102:1092-1101.
11. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, and Yanagisawa M (2000) Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 105:925-933.
12. Hirata Y, Takagi Y, Fukuda Y, and Marumo F (1989) Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 78:225-228.
13. Ikeda U, Yamamoto K, Maeda Y, Shimpo M, Kanbe T, and Shimada K (1997) Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension 29:65-69.
14. Intengan HD and Schiffrin EL (2001) Vascular remodeling in hypertension: roles of apoptosis, inflammation and fibrosis. Hypertension 38:581-587.
15. Kirchengast M and Münter K (1998) Endothelin and restenosis. Cardiovasc Res 39:550-555.
16. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, and Virmani R (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115:1051-1058.
17. Matsumura Y, Kuro T, Kobayashi Y, Konishi F, Takaoka M, Wessale JL, Opgenorth TJ, Gariepy CE, and Yanagisawa M (2000) Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetatesalt hypertension. Circulation 102:2765-2773.
18. McKenna CJ, Burke SE, Opgenorth TJ, Padley RJ, Camrud LJ, Camrud AR, Johnson J, Carlson PJ, Lerman A, Holmes DR Jr, et al. (1998) Selective ETA receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation 97:2551-2556.
19. Miyauchi T and Masaki T (1999) Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 61:391-415.
20. Mori T, Durand J, Chen Y, Thompson JA, Bakir S, and Oparil S (2000) Effects of short-term estrogen treatment on the neointimal response to balloon injury of rat carotid artery. Am J Cardiol 85:1276-1279.
21. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, et al. (2003) Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323.
22. Murakoshi N, Miyauchi T, Kakinuma Y, Ohuchi T, Goto K, Yanagisawa M, and Yamaguchi I (2002) Vascular endothelin-B receptor system in vivo plays a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice. Circulation 106:1991-1998.
23. Nishikibe M, Ohta H, Okada M, Ishikawa K, Hayama T, Fukuroda T, Noguchi K, Saito M, Kanoh T, Ozaki S, et al. (1999) Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist. J Pharmacol Exp Ther 289:1262-1270.
24. Nishida M, Eshiro K, Okada Y, Takaoka M, and Matsumura Y (2004a) Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension. J Cardiovasc Pharmacol 44:187-191.
25. Nishida M, Okada Y, Akiyoshi K, Eshiro K, Takoaka M, Gariepy CE, Yanagisawa M, and Matsumura Y (2004b) Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats. Eur J Pharmacol 496:159-165.
26. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, Gehrke LJ, Hernandez L, Magnuson SR, Marsh KC, et al. (1996) Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276:473-481.
27. Pollock DM and Pollock JS (2001) Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol 281:F144-F150.
28. Porter KE, Olojugba DH, Masood I, Pemberton M, Bell PR, and London NJ (1998) Endothelin-B receptors mediate intimal hyperplasia in an organ culture of human saphenous vein. J Vasc Surg 28:695-701.
29. Sachidanandam K, Portik-Dobos V, Harris AK, Hutchinson JR, Muller E, Johnson MH, and Ergul A (2007) Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes. Diabetes 56:2753-2758.
30. Sanmartín M, Fernández-Ortiz A, Fantidis P, Aragoncillo P, Fernández-Durango R, Rollín R, Alfonso F, Hernández R, Escaned J, and Macaya C (2003) Effects of bosentan on neointimal response following coronary angioplasty. Eur J Clin Invest 33:762-768.
31. Shirai N, Naruko T, Ohsawa M, Ikura Y, Sugama Y, Hirayama M, Kitabayashi C, Ehara S, Inoue T, Itoh A, et al. (2006) Expression of endothelin-converting enzyme, endothelin-1 and endothelin receptors at the site of percutaneous coronary intervention in humans. J Hypertens 24:711-721.
32. Spaulding C, Daemen J, Boersma E, Cutlip DE, and Serruys PW (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:989-997.
33. Takahashi M (2006) The role of endothelin-1 in vascular remodeling in vivo. Cardiovasc Res 71:4-5.
34. Takase H, Sugiyama M, Nakazawa A, Toriyama T, Hayashi K, Goto T, Sato K, Ikeda K, Ueda R, and Dohi Y (2003) Increased endogenous endothelin-1 in coronary circulation is associated with restenosis after coronary angioplasty. Can J Cardiol 19:902-906.
35. Tsukahara H, Ende H, Magazine HI, Bahou WF, and Goligorsky MS (1994) Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells. J Biol Chem 269:21778-21785.
36. von Geldern TW, Tasker AS, Sorensen BK, Winn M, Szczepankiewicz BG, Dixon DB, Chiou WJ, Wang L, Wessale JL, Adler A, et al. (1999) Pyrrolidine-3- carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ETB selectivity. J Med Chem 42:3668-3678.
37. Wang X, Douglas SA, Louden C, Vickery-Clark LM, Feuerstein GZ, and Ohlstein EH (1996) Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res 78:322-328.
38. Williams JM, Pollock JS, and Pollock DM (2004) Arterial pressure response to the antioxidant tempol and ETB receptor. Hypertension 44:770-775.
39. Weintraub WS (2007) The pathophysiology and burden of restenosis. Am J Cardiol 100:3K-9K.
40. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, and Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415.